Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial.

Date publication

avril 2021

Journal

Clinical research in cardiology : official journal of the German Cardiac Society

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Martens P, Ferreira JP, Vincent J, Abreu P, Busselen M, Mullens W, Tang WWH, Böhm M, Pitt B, Zannad F, Rossignol P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33893561

Résumé

Sodium changes are common in myocardial infarction (MI) complicated with left ventricular systolic dysfunction (LVSD) and/or heart failure (HF). Sodium handling is fine-tuned in the distal nephron, were eplerenone exhibits some of its pleotropic effects. Little is known about the effect of eplerenone on serum sodium and the prognostic relevance of sodium alterations in patients with MI complicated with LVSD and/or HF.

Mots clés

Electrolytes, Eplerenone, Heart failure, Hypernatremia, Hyponatremia, Myocardial infarction, Systolic dysfunction

Référence

Clin Res Cardiol. 2021 Apr 23;: